IMVT
Closed
Immunovant inc
16.15
+0.15 (+0.94%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 16.
Day's Range: 15.855 - 16.6981
Send
sign up or login to leave a comment!
When Written:
15.4
Immunovant Inc. is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for patients with autoimmune diseases. The company's lead product candidate, IMVT-1401, is a fully human monoclonal antibody that is designed to target and block the action of the neonatal Fc receptor (FcRn), a protein that plays a key role in the recycling and protection of immunoglobulin G (IgG) antibodies in the body. By inhibiting FcRn, IMVT-1401 has the potential to reduce the levels of pathogenic IgG antibodies that contribute to the development and progression of autoimmune diseases. The company is currently conducting clinical trials of IMVT-1401 in patients with myasthenia gravis and thyroid eye disease, and is also exploring the use of the antibody in other autoimmune conditions. Immunovant Inc. was founded in 2017 and is headquartered in New York, NY. The company is a subsidiary of Roivant Sciences.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








